Key Insights
The European nuclear imaging solutions market, valued at €2.22 billion in 2025, is projected to experience steady growth, driven by a rising geriatric population, increasing prevalence of chronic diseases like cancer and cardiovascular ailments, and technological advancements in imaging techniques like PET and SPECT. The market's compound annual growth rate (CAGR) of 3.34% from 2025 to 2033 reflects a consistent demand for improved diagnostic capabilities and personalized medicine approaches. Key segments within this market include equipment (e.g., scanners, cameras), radioisotopes (like Technetium-99m, Fluorine-18), and associated applications (SPECT and PET scans). Germany, France, and the UK are expected to be the leading national markets within Europe, fueled by robust healthcare infrastructure and high adoption rates of advanced diagnostic technologies. The market's growth, however, may face some challenges, including stringent regulatory hurdles for new radioisotopes, the high cost of equipment and procedures, and potential shortages of qualified nuclear medicine professionals. Strategic partnerships, technological innovations, and focused investments in research and development will likely be crucial for market players to navigate these challenges and sustain growth.
The competitive landscape is characterized by a mix of established players like Siemens Healthineers, GE Healthcare, and Bracco Imaging, along with smaller, specialized companies focusing on specific radioisotopes or imaging modalities. These companies are focusing on developing advanced imaging systems that offer improved resolution, faster scan times, and reduced radiation exposure to patients. The continuous improvement in image quality, coupled with the increasing availability of advanced radiotracers, is set to drive adoption across various applications, especially oncology and cardiology. Furthermore, the trend towards personalized medicine and targeted therapies will further propel the demand for nuclear imaging solutions, ensuring continued market expansion within Europe over the forecast period.
Europe Nuclear Imaging Solutions Industry: A Comprehensive Market Report (2019-2033)
This comprehensive report provides a detailed analysis of the Europe Nuclear Imaging Solutions industry, offering valuable insights for stakeholders, investors, and industry professionals. The report covers the period 2019-2033, with 2025 serving as the base and estimated year. It meticulously examines market trends, competitive dynamics, and growth opportunities, offering actionable intelligence for strategic decision-making. The report segments the market by product (Equipment, Radioisotopes) and application (SPECT, PET), providing granular analysis of key segments and their growth trajectories.
Europe Nuclear Imaging Solutions Industry Market Concentration & Innovation
The European nuclear imaging solutions market exhibits a moderately concentrated structure, with a few major players dominating the landscape. Companies like Siemens Healthineers, GE Healthcare, and Bracco Imaging SpA hold significant market share, driven by their extensive product portfolios and established distribution networks. However, smaller players and specialized companies are also actively contributing to market innovation.
Market Share: Siemens Healthineers and GE Healthcare are estimated to hold a combined market share of approximately xx% in 2025, while Bracco Imaging SpA holds approximately xx%. Other key players, including Nordion Inc, Cardinal Health Inc, Novartis AG (Advanced Accelerator Applications), NTP Radioisotopes SOC, Koninklijke Philips NV, Canon Medical Systems Corporation, Curium, and Merck KGaA (Sigma-Aldrich), contribute to the remaining market share.
Innovation Drivers: The industry is driven by advancements in radioisotope production, the development of novel imaging agents, and technological upgrades in imaging equipment. The increasing demand for advanced diagnostic capabilities and personalized medicine further fuels innovation.
Regulatory Framework: Stringent regulatory approvals and quality control measures influence market dynamics. The European Medicines Agency (EMA) plays a crucial role in shaping industry standards and approvals for new products and technologies.
Product Substitutes: While nuclear imaging enjoys a unique position in diagnostics, alternative imaging modalities such as MRI and CT scans exist, creating competitive pressure.
End-User Trends: The rising prevalence of chronic diseases, the growing demand for early and accurate diagnosis, and the increasing adoption of minimally invasive procedures drive market growth.
M&A Activities: The market has witnessed several mergers and acquisitions in recent years, with deal values ranging from xx Million to xx Million. These activities reflect the industry's consolidation and the strategic efforts of major players to expand their product portfolios and market reach.
Europe Nuclear Imaging Solutions Industry Industry Trends & Insights
The European nuclear imaging solutions market is projected to experience substantial growth during the forecast period (2025-2033), with a Compound Annual Growth Rate (CAGR) of approximately xx%. Several key factors contribute to this growth:
Technological advancements: Continuous improvements in imaging equipment, such as SPECT/CT and PET/CT systems, improve image quality and diagnostic accuracy, driving market penetration.
Growing prevalence of chronic diseases: The increasing incidence of cancer, cardiovascular diseases, and neurological disorders fuels the demand for accurate and timely diagnostics.
Rising healthcare expenditure: Increasing healthcare budgets in several European countries provide greater access to advanced imaging technologies.
Demand for personalized medicine: Nuclear imaging plays a crucial role in tailoring treatment strategies to individual patient needs, leading to increased adoption.
Regulatory support and reimbursement policies: Favorable regulatory frameworks and increasing healthcare insurance coverage incentivize the use of nuclear imaging techniques.
Competitive landscape: The presence of established players and emerging innovative companies fosters competition, driving innovation and creating opportunities for market expansion.
Dominant Markets & Segments in Europe Nuclear Imaging Solutions Industry
Germany, France, and the United Kingdom represent the dominant markets within Europe for nuclear imaging solutions. This dominance stems from several factors:
Key Drivers:
- Advanced healthcare infrastructure: These countries have well-established healthcare systems with robust infrastructure to support the implementation and utilization of nuclear imaging technologies.
- High healthcare expenditure: Significant investments in healthcare and higher healthcare spending per capita contribute to greater affordability and accessibility of nuclear imaging services.
- Strong research and development activities: These regions have a strong presence of research institutions and pharmaceutical companies engaged in developing advanced nuclear imaging solutions.
- Favorable regulatory environment: The regulatory landscape in these countries encourages innovation and supports the adoption of new technologies.
Dominance Analysis: Germany's large population and advanced medical infrastructure make it a leading market. France and the UK, with their substantial healthcare systems and research capabilities, also hold significant market shares. The dominance is further solidified by the presence of major manufacturers and distributors within these regions.
Among the product segments, radioisotopes, particularly Technetium-99m (Tc-99m), hold the largest market share due to their widespread use in SPECT imaging. Within applications, SPECT applications dominate currently, followed by PET applications with significant growth potential.
Europe Nuclear Imaging Solutions Industry Product Developments
Recent advancements focus on improving image quality, enhancing diagnostic accuracy, and developing more targeted radiopharmaceuticals. The integration of AI and machine learning is transforming image analysis, streamlining workflows, and improving diagnostic precision. The trend toward theranostics – combining diagnostics and therapeutics – promises to revolutionize cancer care. These product advancements enhance market competitiveness and cater to the growing demand for sophisticated diagnostic solutions.
Report Scope & Segmentation Analysis
This report segments the European nuclear imaging solutions market comprehensively by product and application. The Product segment includes: Equipment (SPECT/CT, PET/CT, gamma cameras etc.), and Radioisotopes (SPECT Radioisotopes - Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium (Ga-67), and Others; PET Radioisotopes - Fluorine-18 (F-18), Rubidium-82 (Rb-82), and Others). The Application segment encompasses SPECT Applications (cardiology, oncology, neurology etc.) and PET Applications (oncology, neurology etc.). Each segment's market size, growth projections, and competitive dynamics are thoroughly analyzed, providing a complete overview of the industry landscape.
Key Drivers of Europe Nuclear Imaging Solutions Industry Growth
The growth of the European nuclear imaging solutions market is fueled by several factors. Technological advancements leading to improved image quality and accuracy are key drivers. The rising prevalence of chronic diseases increases the demand for diagnostic tools. Favorable regulatory frameworks and healthcare policies further stimulate market expansion. Finally, growing investments in healthcare infrastructure in several European countries are creating significant opportunities for market growth.
Challenges in the Europe Nuclear Imaging Solutions Industry Sector
The industry faces several challenges, including stringent regulatory hurdles and the complexities involved in obtaining approvals for new radiopharmaceuticals. The cost of equipment and radioisotopes poses a barrier to access for some healthcare providers. Competition from other imaging modalities also presents a challenge. These factors can affect market growth and profitability. The dependence on a limited number of suppliers for radioisotopes also poses supply chain vulnerability.
Emerging Opportunities in Europe Nuclear Imaging Solutions Industry
Emerging opportunities lie in the development of novel radiopharmaceuticals, the integration of AI and machine learning in image analysis, and the expansion of theranostic applications. The increasing demand for personalized medicine presents significant potential. Focus on improving patient access and affordability is also crucial for market expansion.
Leading Players in the Europe Nuclear Imaging Solutions Industry Market
- Nordion Inc
- Siemens Healthineers
- GE Healthcare
- Bracco Imaging SpA
- Cardinal Health Inc
- Novartis AG (Advanced Accelerator Applications)
- NTP Radioisotopes SOC
- Koninklijke Philips NV
- Canon Medical Systems Corporation
- Curium
- Merck KGaA (Sigma-Aldrich)
- *List Not Exhaustive
Key Developments in Europe Nuclear Imaging Solutions Industry Industry
September 2023: Lantheus Holdings, Inc. announced that PYLARIFY AI data will be presented at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting in Vienna, Austria. This highlights the growing role of AI in nuclear imaging.
December 2022: The European Commission (EC) approved Novartis's Pluvicto for the treatment of PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). This approval expands treatment options and signifies progress in targeted radioligand therapy.
Strategic Outlook for Europe Nuclear Imaging Solutions Industry Market
The European nuclear imaging solutions market is poised for continued growth, driven by technological innovation, increasing disease prevalence, and supportive regulatory environments. Opportunities exist in personalized medicine, AI-driven image analysis, and the development of novel radiopharmaceuticals. Strategic partnerships and investments in research and development will be crucial for maximizing growth potential in this dynamic market.
Europe Nuclear Imaging Solutions Industry Segmentation
-
1. Product
- 1.1. Equipment
-
1.2. Radioisotope
-
1.2.1. SPECT Radioisotopes
- 1.2.1.1. Technetium-99m (TC-99m)
- 1.2.1.2. Thallium-201 (TI-201)
- 1.2.1.3. Gallium(Ga-67)
- 1.2.1.4. Other SPECT Radioisotopes
-
1.2.2. PET Radioisotopes
- 1.2.2.1. Fluorine-18 (F-18)
- 1.2.2.2. Rubidium-82 (RB-82)
- 1.2.2.3. Other PET Radioisotopes
-
1.2.1. SPECT Radioisotopes
-
2. Application
-
2.1. SPECT Applications
- 2.1.1. Cardiology
- 2.1.2. Neurology
- 2.1.3. Thyroid
- 2.1.4. Other SPECT Applications
-
2.2. PET Applications
- 2.2.1. Oncology
- 2.2.2. Other PET Applications
-
2.1. SPECT Applications
Europe Nuclear Imaging Solutions Industry Segmentation By Geography
- 1. Germany
- 2. United Kingdom
- 3. France
- 4. Italy
- 5. Spain
- 6. Rest of Europe
Europe Nuclear Imaging Solutions Industry REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2019-2033 |
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2025-2033 |
| Historical Period | 2019-2024 |
| Growth Rate | CAGR of 3.34% from 2019-2033 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Rise in Prevalence of Cancer and Cardiac Disorders; Growth in Applications of Nuclear Medicine and Imaging and Rising Technological Advancements
- 3.3. Market Restrains
- 3.3.1. Regulatory Issues and Lack of Reimbursement
- 3.4. Market Trends
- 3.4.1. Equipment Segment Expects to Witness Significant Growth Over the Forecast Period
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Europe Nuclear Imaging Solutions Industry Analysis, Insights and Forecast, 2019-2031
- 5.1. Market Analysis, Insights and Forecast - by Product
- 5.1.1. Equipment
- 5.1.2. Radioisotope
- 5.1.2.1. SPECT Radioisotopes
- 5.1.2.1.1. Technetium-99m (TC-99m)
- 5.1.2.1.2. Thallium-201 (TI-201)
- 5.1.2.1.3. Gallium(Ga-67)
- 5.1.2.1.4. Other SPECT Radioisotopes
- 5.1.2.2. PET Radioisotopes
- 5.1.2.2.1. Fluorine-18 (F-18)
- 5.1.2.2.2. Rubidium-82 (RB-82)
- 5.1.2.2.3. Other PET Radioisotopes
- 5.1.2.1. SPECT Radioisotopes
- 5.2. Market Analysis, Insights and Forecast - by Application
- 5.2.1. SPECT Applications
- 5.2.1.1. Cardiology
- 5.2.1.2. Neurology
- 5.2.1.3. Thyroid
- 5.2.1.4. Other SPECT Applications
- 5.2.2. PET Applications
- 5.2.2.1. Oncology
- 5.2.2.2. Other PET Applications
- 5.2.1. SPECT Applications
- 5.3. Market Analysis, Insights and Forecast - by Region
- 5.3.1. Germany
- 5.3.2. United Kingdom
- 5.3.3. France
- 5.3.4. Italy
- 5.3.5. Spain
- 5.3.6. Rest of Europe
- 5.1. Market Analysis, Insights and Forecast - by Product
- 6. Germany Europe Nuclear Imaging Solutions Industry Analysis, Insights and Forecast, 2019-2031
- 6.1. Market Analysis, Insights and Forecast - by Product
- 6.1.1. Equipment
- 6.1.2. Radioisotope
- 6.1.2.1. SPECT Radioisotopes
- 6.1.2.1.1. Technetium-99m (TC-99m)
- 6.1.2.1.2. Thallium-201 (TI-201)
- 6.1.2.1.3. Gallium(Ga-67)
- 6.1.2.1.4. Other SPECT Radioisotopes
- 6.1.2.2. PET Radioisotopes
- 6.1.2.2.1. Fluorine-18 (F-18)
- 6.1.2.2.2. Rubidium-82 (RB-82)
- 6.1.2.2.3. Other PET Radioisotopes
- 6.1.2.1. SPECT Radioisotopes
- 6.2. Market Analysis, Insights and Forecast - by Application
- 6.2.1. SPECT Applications
- 6.2.1.1. Cardiology
- 6.2.1.2. Neurology
- 6.2.1.3. Thyroid
- 6.2.1.4. Other SPECT Applications
- 6.2.2. PET Applications
- 6.2.2.1. Oncology
- 6.2.2.2. Other PET Applications
- 6.2.1. SPECT Applications
- 6.1. Market Analysis, Insights and Forecast - by Product
- 7. United Kingdom Europe Nuclear Imaging Solutions Industry Analysis, Insights and Forecast, 2019-2031
- 7.1. Market Analysis, Insights and Forecast - by Product
- 7.1.1. Equipment
- 7.1.2. Radioisotope
- 7.1.2.1. SPECT Radioisotopes
- 7.1.2.1.1. Technetium-99m (TC-99m)
- 7.1.2.1.2. Thallium-201 (TI-201)
- 7.1.2.1.3. Gallium(Ga-67)
- 7.1.2.1.4. Other SPECT Radioisotopes
- 7.1.2.2. PET Radioisotopes
- 7.1.2.2.1. Fluorine-18 (F-18)
- 7.1.2.2.2. Rubidium-82 (RB-82)
- 7.1.2.2.3. Other PET Radioisotopes
- 7.1.2.1. SPECT Radioisotopes
- 7.2. Market Analysis, Insights and Forecast - by Application
- 7.2.1. SPECT Applications
- 7.2.1.1. Cardiology
- 7.2.1.2. Neurology
- 7.2.1.3. Thyroid
- 7.2.1.4. Other SPECT Applications
- 7.2.2. PET Applications
- 7.2.2.1. Oncology
- 7.2.2.2. Other PET Applications
- 7.2.1. SPECT Applications
- 7.1. Market Analysis, Insights and Forecast - by Product
- 8. France Europe Nuclear Imaging Solutions Industry Analysis, Insights and Forecast, 2019-2031
- 8.1. Market Analysis, Insights and Forecast - by Product
- 8.1.1. Equipment
- 8.1.2. Radioisotope
- 8.1.2.1. SPECT Radioisotopes
- 8.1.2.1.1. Technetium-99m (TC-99m)
- 8.1.2.1.2. Thallium-201 (TI-201)
- 8.1.2.1.3. Gallium(Ga-67)
- 8.1.2.1.4. Other SPECT Radioisotopes
- 8.1.2.2. PET Radioisotopes
- 8.1.2.2.1. Fluorine-18 (F-18)
- 8.1.2.2.2. Rubidium-82 (RB-82)
- 8.1.2.2.3. Other PET Radioisotopes
- 8.1.2.1. SPECT Radioisotopes
- 8.2. Market Analysis, Insights and Forecast - by Application
- 8.2.1. SPECT Applications
- 8.2.1.1. Cardiology
- 8.2.1.2. Neurology
- 8.2.1.3. Thyroid
- 8.2.1.4. Other SPECT Applications
- 8.2.2. PET Applications
- 8.2.2.1. Oncology
- 8.2.2.2. Other PET Applications
- 8.2.1. SPECT Applications
- 8.1. Market Analysis, Insights and Forecast - by Product
- 9. Italy Europe Nuclear Imaging Solutions Industry Analysis, Insights and Forecast, 2019-2031
- 9.1. Market Analysis, Insights and Forecast - by Product
- 9.1.1. Equipment
- 9.1.2. Radioisotope
- 9.1.2.1. SPECT Radioisotopes
- 9.1.2.1.1. Technetium-99m (TC-99m)
- 9.1.2.1.2. Thallium-201 (TI-201)
- 9.1.2.1.3. Gallium(Ga-67)
- 9.1.2.1.4. Other SPECT Radioisotopes
- 9.1.2.2. PET Radioisotopes
- 9.1.2.2.1. Fluorine-18 (F-18)
- 9.1.2.2.2. Rubidium-82 (RB-82)
- 9.1.2.2.3. Other PET Radioisotopes
- 9.1.2.1. SPECT Radioisotopes
- 9.2. Market Analysis, Insights and Forecast - by Application
- 9.2.1. SPECT Applications
- 9.2.1.1. Cardiology
- 9.2.1.2. Neurology
- 9.2.1.3. Thyroid
- 9.2.1.4. Other SPECT Applications
- 9.2.2. PET Applications
- 9.2.2.1. Oncology
- 9.2.2.2. Other PET Applications
- 9.2.1. SPECT Applications
- 9.1. Market Analysis, Insights and Forecast - by Product
- 10. Spain Europe Nuclear Imaging Solutions Industry Analysis, Insights and Forecast, 2019-2031
- 10.1. Market Analysis, Insights and Forecast - by Product
- 10.1.1. Equipment
- 10.1.2. Radioisotope
- 10.1.2.1. SPECT Radioisotopes
- 10.1.2.1.1. Technetium-99m (TC-99m)
- 10.1.2.1.2. Thallium-201 (TI-201)
- 10.1.2.1.3. Gallium(Ga-67)
- 10.1.2.1.4. Other SPECT Radioisotopes
- 10.1.2.2. PET Radioisotopes
- 10.1.2.2.1. Fluorine-18 (F-18)
- 10.1.2.2.2. Rubidium-82 (RB-82)
- 10.1.2.2.3. Other PET Radioisotopes
- 10.1.2.1. SPECT Radioisotopes
- 10.2. Market Analysis, Insights and Forecast - by Application
- 10.2.1. SPECT Applications
- 10.2.1.1. Cardiology
- 10.2.1.2. Neurology
- 10.2.1.3. Thyroid
- 10.2.1.4. Other SPECT Applications
- 10.2.2. PET Applications
- 10.2.2.1. Oncology
- 10.2.2.2. Other PET Applications
- 10.2.1. SPECT Applications
- 10.1. Market Analysis, Insights and Forecast - by Product
- 11. Rest of Europe Europe Nuclear Imaging Solutions Industry Analysis, Insights and Forecast, 2019-2031
- 11.1. Market Analysis, Insights and Forecast - by Product
- 11.1.1. Equipment
- 11.1.2. Radioisotope
- 11.1.2.1. SPECT Radioisotopes
- 11.1.2.1.1. Technetium-99m (TC-99m)
- 11.1.2.1.2. Thallium-201 (TI-201)
- 11.1.2.1.3. Gallium(Ga-67)
- 11.1.2.1.4. Other SPECT Radioisotopes
- 11.1.2.2. PET Radioisotopes
- 11.1.2.2.1. Fluorine-18 (F-18)
- 11.1.2.2.2. Rubidium-82 (RB-82)
- 11.1.2.2.3. Other PET Radioisotopes
- 11.1.2.1. SPECT Radioisotopes
- 11.2. Market Analysis, Insights and Forecast - by Application
- 11.2.1. SPECT Applications
- 11.2.1.1. Cardiology
- 11.2.1.2. Neurology
- 11.2.1.3. Thyroid
- 11.2.1.4. Other SPECT Applications
- 11.2.2. PET Applications
- 11.2.2.1. Oncology
- 11.2.2.2. Other PET Applications
- 11.2.1. SPECT Applications
- 11.1. Market Analysis, Insights and Forecast - by Product
- 12. Germany Europe Nuclear Imaging Solutions Industry Analysis, Insights and Forecast, 2019-2031
- 13. France Europe Nuclear Imaging Solutions Industry Analysis, Insights and Forecast, 2019-2031
- 14. Italy Europe Nuclear Imaging Solutions Industry Analysis, Insights and Forecast, 2019-2031
- 15. United Kingdom Europe Nuclear Imaging Solutions Industry Analysis, Insights and Forecast, 2019-2031
- 16. Netherlands Europe Nuclear Imaging Solutions Industry Analysis, Insights and Forecast, 2019-2031
- 17. Sweden Europe Nuclear Imaging Solutions Industry Analysis, Insights and Forecast, 2019-2031
- 18. Rest of Europe Europe Nuclear Imaging Solutions Industry Analysis, Insights and Forecast, 2019-2031
- 19. Competitive Analysis
- 19.1. Market Share Analysis 2024
- 19.2. Company Profiles
- 19.2.1 Nordion Inc
- 19.2.1.1. Overview
- 19.2.1.2. Products
- 19.2.1.3. SWOT Analysis
- 19.2.1.4. Recent Developments
- 19.2.1.5. Financials (Based on Availability)
- 19.2.2 Siemens Healthineers
- 19.2.2.1. Overview
- 19.2.2.2. Products
- 19.2.2.3. SWOT Analysis
- 19.2.2.4. Recent Developments
- 19.2.2.5. Financials (Based on Availability)
- 19.2.3 GE Healthcare
- 19.2.3.1. Overview
- 19.2.3.2. Products
- 19.2.3.3. SWOT Analysis
- 19.2.3.4. Recent Developments
- 19.2.3.5. Financials (Based on Availability)
- 19.2.4 Bracco Imaging SpA
- 19.2.4.1. Overview
- 19.2.4.2. Products
- 19.2.4.3. SWOT Analysis
- 19.2.4.4. Recent Developments
- 19.2.4.5. Financials (Based on Availability)
- 19.2.5 Cardinal Health Inc
- 19.2.5.1. Overview
- 19.2.5.2. Products
- 19.2.5.3. SWOT Analysis
- 19.2.5.4. Recent Developments
- 19.2.5.5. Financials (Based on Availability)
- 19.2.6 Novartis AG (Advanced Accelerator Applications)
- 19.2.6.1. Overview
- 19.2.6.2. Products
- 19.2.6.3. SWOT Analysis
- 19.2.6.4. Recent Developments
- 19.2.6.5. Financials (Based on Availability)
- 19.2.7 NTP Radioisotopes SOC
- 19.2.7.1. Overview
- 19.2.7.2. Products
- 19.2.7.3. SWOT Analysis
- 19.2.7.4. Recent Developments
- 19.2.7.5. Financials (Based on Availability)
- 19.2.8 Koninklijke Philips NV
- 19.2.8.1. Overview
- 19.2.8.2. Products
- 19.2.8.3. SWOT Analysis
- 19.2.8.4. Recent Developments
- 19.2.8.5. Financials (Based on Availability)
- 19.2.9 Canon Medical Systems Corporation
- 19.2.9.1. Overview
- 19.2.9.2. Products
- 19.2.9.3. SWOT Analysis
- 19.2.9.4. Recent Developments
- 19.2.9.5. Financials (Based on Availability)
- 19.2.10 Curium
- 19.2.10.1. Overview
- 19.2.10.2. Products
- 19.2.10.3. SWOT Analysis
- 19.2.10.4. Recent Developments
- 19.2.10.5. Financials (Based on Availability)
- 19.2.11 Merck KGaA (Sigma-Aldrich)*List Not Exhaustive
- 19.2.11.1. Overview
- 19.2.11.2. Products
- 19.2.11.3. SWOT Analysis
- 19.2.11.4. Recent Developments
- 19.2.11.5. Financials (Based on Availability)
- 19.2.1 Nordion Inc
List of Figures
- Figure 1: Europe Nuclear Imaging Solutions Industry Revenue Breakdown (Million, %) by Product 2024 & 2032
- Figure 2: Europe Nuclear Imaging Solutions Industry Share (%) by Company 2024
List of Tables
- Table 1: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Region 2019 & 2032
- Table 2: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Product 2019 & 2032
- Table 3: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Application 2019 & 2032
- Table 4: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Region 2019 & 2032
- Table 5: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 6: Germany Europe Nuclear Imaging Solutions Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 7: France Europe Nuclear Imaging Solutions Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 8: Italy Europe Nuclear Imaging Solutions Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 9: United Kingdom Europe Nuclear Imaging Solutions Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 10: Netherlands Europe Nuclear Imaging Solutions Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 11: Sweden Europe Nuclear Imaging Solutions Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 12: Rest of Europe Europe Nuclear Imaging Solutions Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 13: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Product 2019 & 2032
- Table 14: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Application 2019 & 2032
- Table 15: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 16: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Product 2019 & 2032
- Table 17: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Application 2019 & 2032
- Table 18: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 19: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Product 2019 & 2032
- Table 20: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Application 2019 & 2032
- Table 21: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 22: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Product 2019 & 2032
- Table 23: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Application 2019 & 2032
- Table 24: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 25: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Product 2019 & 2032
- Table 26: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Application 2019 & 2032
- Table 27: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 28: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Product 2019 & 2032
- Table 29: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Application 2019 & 2032
- Table 30: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Country 2019 & 2032
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Europe Nuclear Imaging Solutions Industry?
The projected CAGR is approximately 3.34%.
2. Which companies are prominent players in the Europe Nuclear Imaging Solutions Industry?
Key companies in the market include Nordion Inc, Siemens Healthineers, GE Healthcare, Bracco Imaging SpA, Cardinal Health Inc, Novartis AG (Advanced Accelerator Applications), NTP Radioisotopes SOC, Koninklijke Philips NV, Canon Medical Systems Corporation, Curium, Merck KGaA (Sigma-Aldrich)*List Not Exhaustive.
3. What are the main segments of the Europe Nuclear Imaging Solutions Industry?
The market segments include Product, Application.
4. Can you provide details about the market size?
The market size is estimated to be USD 2.22 Million as of 2022.
5. What are some drivers contributing to market growth?
Rise in Prevalence of Cancer and Cardiac Disorders; Growth in Applications of Nuclear Medicine and Imaging and Rising Technological Advancements.
6. What are the notable trends driving market growth?
Equipment Segment Expects to Witness Significant Growth Over the Forecast Period.
7. Are there any restraints impacting market growth?
Regulatory Issues and Lack of Reimbursement.
8. Can you provide examples of recent developments in the market?
September 2023: Lantheus Holdings, Inc. reported PYLARIFY AI data will be presented at the upcoming 2023 European Association of Nuclear Medicine (EANM) Annual Meeting, which will be held in Vienna, Austria.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in Million.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Europe Nuclear Imaging Solutions Industry," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Europe Nuclear Imaging Solutions Industry report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Europe Nuclear Imaging Solutions Industry?
To stay informed about further developments, trends, and reports in the Europe Nuclear Imaging Solutions Industry, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
